Combined effects of genetic and non‐genetic risk factors affect response to ranibizumab in exudative age‐related macular degeneration

To investigate whether genetic and non‐genetic risk factors influence 12‐month response to ranibizumab treatment for exudative age‐related macular degeneration (AMD).

[1]  S. Piermarocchi,et al.  Re: Hagstrom et al.: Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT) (Ophthalmology 2013;120:593-9). , 2014, Ophthalmology.

[2]  Gabriëlle H S Buitendijk,et al.  Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. , 2014, Ophthalmology.

[3]  S. Harding,et al.  Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. , 2013, Ophthalmology.

[4]  S. Song,et al.  Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration , 2013, Journal of Korean medical science.

[5]  S. Quéré,et al.  CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The LUMIERE Study , 2013, Retina.

[6]  Ivana K. Kim,et al.  Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). , 2013, Ophthalmology.

[7]  B. J. Klevering,et al.  Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.

[8]  Aaron Y. Lee,et al.  Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes. , 2012, Ophthalmology.

[9]  B. J. Klevering,et al.  Cumulative Effect of High Risk Alleles in CFH, ARMS2 and VEGF on Response to Ranibizumab Treatment in Age-Related Macular Degeneration , 2012 .

[10]  Gary C. Brown,et al.  ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2012, Retina.

[11]  A. Bansal,et al.  Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration , 2011, Human Genomics.

[12]  C. Klaver,et al.  Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study. , 2011, Archives of ophthalmology.

[13]  W. Berger,et al.  Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.

[14]  D. Paikl,et al.  Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age‐related macular degeneration , 2011, Acta ophthalmologica.

[15]  Margaret A. Pericak-Vance,et al.  Using Genetic Variation and Environmental Risk Factor Data to Identify Individuals at High Risk for Age-Related Macular Degeneration , 2011, PloS one.

[16]  P. Rosenfeld,et al.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.

[17]  S. Teper,et al.  Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration , 2010, Molecular vision.

[18]  J. Sahel,et al.  Genotypic influences on severity of exudative age-related macular degeneration. , 2010, Investigative ophthalmology & visual science.

[19]  Eric N Brown,et al.  Complement, age-related macular degeneration and a vision of the future. , 2010, Archives of ophthalmology.

[20]  S. Hawken,et al.  A genetic approach to stratification of risk for age-related macular degeneration. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[21]  Ivana K. Kim,et al.  Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. , 2009, American journal of ophthalmology.

[22]  M. Daly,et al.  Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.

[23]  R. Hogg,et al.  GENOTYPE–PHENOTYPE ASSOCIATIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2009, Retina.

[24]  E. Souied,et al.  Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes. , 2008, Investigative ophthalmology & visual science.

[25]  J. Haines,et al.  C3 R102G polymorphism increases risk of age-related macular degeneration. , 2008, Human molecular genetics.

[26]  P. Tommila,et al.  Complement factor H Y402H polymorphism and characteristics of exudative age‐related macular degeneration lesions , 2008, Acta ophthalmologica.

[27]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[28]  Gonçalo R. Abecasis,et al.  A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration , 2007, Proceedings of the National Academy of Sciences.

[29]  C. Klaver,et al.  Predictive value of multiple genetic testing for age-related macular degeneration. , 2007, Archives of ophthalmology.

[30]  B. Rosner,et al.  Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. , 2007, JAMA.

[31]  W. März,et al.  Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. , 2007, Ophthalmology.

[32]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[33]  G. Ying,et al.  Effect of systemic hypertension on foveolar choroidal blood flow in age related macular degeneration , 2006, British Journal of Ophthalmology.

[34]  P. Mitchell,et al.  Smoking and age-related macular degeneration: a review of association , 2005, Eye.

[35]  Johanna M Seddon,et al.  The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. , 2005, Archives of ophthalmology.

[36]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[37]  Johanna M Seddon,et al.  Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. , 2003, Ophthalmology.

[38]  Ronald Klein,et al.  The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. , 2003, Ophthalmology.

[39]  Frank Eperjesi,et al.  Risk Factors for Age-related Macular Degeneration , 2011 .

[40]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[41]  A. Malarcher,et al.  State-specific secondhand smoke exposure and current cigarette smoking among adults - United States, 2008. , 2009, MMWR. Morbidity and mortality weekly report.

[42]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[43]  Lars G Fritsche,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. , 2005, Human molecular genetics.

[44]  I. Suñer,et al.  Nicotine increases size and severity of experimental choroidal neovascularization. , 2004, Investigative ophthalmology & visual science.

[45]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[46]  Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. , 2000, Ophthalmology.